Fleming AD, Mellor J, Jiang W, Storkey A, Styles CJ, McKeigue PM, Colhoun HM. Safe and efficient 2-year screening intervals allocated by manual and automated grading in nationwide diabetic retinopathy screening. Poster presented at the 58th EASD Annual Meeting; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(supplement 1):372. doi: 10.1007/s00125-022-05755-w
Mellor J, Jiang W, Fleming AD, Styles CJ, Storkey A, McKeigue PM, Colhoun HM, Scottish Diabetes Research Network. Evaluation of deep learning prediction models for cardiovascular risk prediction using fundus images from the Scottish Diabetic Retinopathy Screening programme. Poster presented at the 58th EASD Annual Meeting of the European Association for the Study of Diabetes; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(Supple 1):S408-9. doi: 10.1007/s00125-022-05755-w
Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Berria R, Rosenstock J, Silberman C, Davis KL, Horton ES. Weight loss and associated changes in glycaemic control and cardiovascular biomarkers in patients with type 2 diabetes mellitus receiving incretin therapies in a large cohort database. Poster presented at the 44th General Assembly of the European Association for the Study of Diabetes; September 2009. [abstract] Diabetologia. 2009 Sep; 52(Suppl. 1, Abst.755):S297.